Subcutaneous Epcoritamab + R-Dhax/C in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Eligible for Autologous Stem Cell Transplant: Updated Phase 1/2 Results

Category Primary study
JournalBlood
Year 2022
This article has no abstract
Epistemonikos ID: 1d25164f08125f7b73cd89cc725dde57b0844ab3
First added on: Feb 16, 2025